Cargando…
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
BACKGROUND: Significant anxiety symptoms are associated with poor clinical course and outcome in major depressive disorder (MDD). This single-arm, open-label study aimed to evaluate the efficacy and tolerability of escitalopram treatment in patients with MDD and anxiety symptoms. METHODS: Adult pati...
Autores principales: | Jiang, Kaida, Li, Lingjiang, Wang, Xueyi, Fang, Maosheng, Shi, Jianfei, Cao, Qiuyun, He, Jincai, Wang, Jinan, Tan, Weihao, Hu, Cuili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322850/ https://www.ncbi.nlm.nih.gov/pubmed/28255239 http://dx.doi.org/10.2147/NDT.S120190 |
Ejemplares similares
-
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
por: Wang, Gang, et al.
Publicado: (2018) -
Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011) -
An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus
Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022) -
Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021) -
Resistant social anxiety disorder response to Escitalopram
por: Pallanti, Stefano, et al.
Publicado: (2006)